FierceVaccines celebrates the holidays

Another year is over, and FierceVaccines is taking some time off to relax and celebrate the upcoming holidays. The newsletter won't be published next week, but we'll return to our regular schedule on Thursday, Jan. 5. Before we head out, I'd like to share a few useful links:

  • The most-read feature of 2011 was the report on 10 promising therapeutic vaccines. If you missed it the first time around, you can click here to view the report. Our sister publications have filed dozens of additional special reports, which you can view by visiting this page.
  • Our most-read news story was an interview with Pfizer vaccine chief Emilio Emini.
  • Did you know FierceVaccines has extensive archives? Check out our tag page, which contains hundreds of links to relevant vaccine industry topics.

As always, we want to thank you for being part of the FierceVaccines community. I wish you a wonderful holiday and look forward to seeing you back here next year. — Maureen Martino (twitter | email)

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.